SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 5, 2025-- Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that the U.S.

PH284 nasal spray demonstrated improvements to subjective feelings of hunger in cancer patients PH284 is the fifth pherine product candidate in Vistagen’s neuroscience pipeline with a positive efficacy signal SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan.

All planned clinical studies in fasedienol U.S. registration-directed Phase 3 program for the acute treatment of social anxiety disorder are underway SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan. 10, 2025-- Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 14, 2024-- Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced that company management will present and host one-on-one meetings during the Stifel 2024

Fasedienol U.S. registration-directed PALISADE Phase 3 Program for acute treatment of social anxiety disorder progressing PALISADE-3 and PALISADE-4 Phase 3 trials initiated and underway SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 7, 2024-- Vistagen (Nasdaq: VTGN), a late clinical-stage

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 5, 2024-- Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced that it will present posters highlighting new prevalence data for social anxiety disorder

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 1, 2024-- Vistagen (NASDAQ: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced it will host a conference call and webcast on Thursday, November 7, 2024 , at 2:00 p.m.

Vistagen CEO Shawn Singh ; The Goldie Hawn Foundation Founder Goldie Hawn ; and MindUP students to ring the Nasdaq Closing Bell on October 10, 2024 Vistagen and The Goldie Hawn Foundation join forces to raise awareness around the roles of mindfulness and pioneering neuroscience in mental health

Next step in registration-directed PALISADE Phase 3 program for fasedienol in social anxiety disorder achieved as planned SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 23, 2024-- Vistagen (Nasdaq: VTGN) a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the

PALISADE Phase 3 Program for the acute treatment of Social Anxiety Disorder progressing on track SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 13, 2024-- Vistagen (Nasdaq: VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and